These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21802118)

  • 1. A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism.
    Rondina MT; Wanner N; Pendleton RC; Kraiss LW; Vinik R; Zimmerman GA; Heilbrun M; Hoffman JM; Morton KA
    Thromb Res; 2012 Jan; 129(1):22-7. PubMed ID: 21802118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.
    Robin P; Le Roux PY; Planquette B; Accassat S; Roy PM; Couturaud F; Ghazzar N; Prevot-Bitot N; Couturier O; Delluc A; Sanchez O; Tardy B; Le Gal G; Salaun PY;
    Lancet Oncol; 2016 Feb; 17(2):193-199. PubMed ID: 26672686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for occult malignancy with FDG-PET/CT in patients with unprovoked venous thromboembolism.
    Alfonso A; Redondo M; Rubio T; Del Olmo B; Rodríguez-Wilhelmi P; García-Velloso MJ; Richter JA; Páramo JA; Lecumberri R
    Int J Cancer; 2013 Nov; 133(9):2157-64. PubMed ID: 23616232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
    Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
    Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of 18F-fluorodesoxyglucose positron-emission tomography combined with low-dose computed tomography for cancer screening in patients with unprovoked venous thromboembolism.
    Robin P; Le Roux PY; Lacut K; Planquette B; Prévot-Bitot N; Lavigne C; Pastre J; Merah A; Le Gal G; Salaun PY
    PLoS One; 2017; 12(6):e0178849. PubMed ID: 28570648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography combined with computed tomography as a screening tool for occult malignancy in patients with unprovoked venous thromboembolism: an observational study.
    Chauchard M; Benali K; Papo T; Sacre K
    Medicine (Baltimore); 2014 Nov; 93(21):e110. PubMed ID: 25380083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism.
    Robin P; Le Roux PY; Le Moigne E; Planquette B; Prévot-Bitot N; Roy PM; Pastre J; Merah A; Couturaud F; Le Gal G; Salaun PY
    Thromb Res; 2017 Jul; 155():6-9. PubMed ID: 28460260
    [No Abstract]   [Full Text] [Related]  

  • 8. Performance of
    Robin P; van Es N; Le Roux PY; Rondina M; Lecumberri R; Beckers M; Le Gal G; Salaun PY
    Thromb Res; 2020 Oct; 194():153-157. PubMed ID: 32788108
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Delluc A; Robin P
    Thromb Res; 2022 May; 213 Suppl 1():S42-S45. PubMed ID: 36210560
    [No Abstract]   [Full Text] [Related]  

  • 10. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
    Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA
    Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
    Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
    J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism.
    Coyle K; Carrier M; Lazo-Langner A; Shivakumar S; Zarychanski R; Tagalakis V; Solymoss S; Routhier N; Douketis J; Coyle D
    Thromb Res; 2017 Mar; 151():67-71. PubMed ID: 28160670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
    Robertson L; Yeoh SE; Stansby G; Agarwal R
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010837. PubMed ID: 28832905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: a comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience.
    Povoski SP; Hall NC; Murrey DA; Chow AZ; Gaglani JR; Bahnson EE; Mojzisik CM; Kuhrt MP; Hitchcock CL; Knopp MV; Martin EW
    World J Surg Oncol; 2011 Nov; 9():152. PubMed ID: 22112047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications.
    Maliha PG; Hudson M; Abikhzer G; Singerman J; Probst S
    Nucl Med Commun; 2019 Apr; 40(4):377-382. PubMed ID: 30664602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of FDG PET/CT imaging for venous thromboembolic disorders: preliminary results from a prospective, observational pilot study.
    Hess S; Madsen PH; Iversen ED; Frifelt JJ; Høilund-Carlsen PF; Alavi A
    Clin Nucl Med; 2015 Jan; 40(1):e23-6. PubMed ID: 24999680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of additional abdominopelvic CT in detecting occult cancer in patients with unprovoked venous thromboembolism.
    Vaidyanathan S; Walsh J; Cliffe H; Saleem N; Weston MJ; Lowe AS; Chowdhury FU
    Clin Radiol; 2016 Jun; 71(6):501-6. PubMed ID: 27005017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unprovoked venous thromboembolism in women over 40: is screening for occult malignancy with mammography and abdominopelvic CT of benefit?
    Healy NA; Daley FC; Sinnatamby R
    Clin Radiol; 2020 Oct; 75(10):757-762. PubMed ID: 32646605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-Body
    Lebech AM; Gaardsting A; Loft A; Graff J; Markova E; Bertelsen AK; Madsen JL; Andersen KF; Benzon EV; Helms M; Mathiesen LR; David KP; Kronborg G; Kjaer A
    J Nucl Med; 2017 Jul; 58(7):1058-1064. PubMed ID: 28082437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
    Kawata S; Imaizumi M; Kako Y; Oku N
    Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.